Paradigm Health vs Triomics (2026)
Both work inside provider organizations to bring trials to patients in routine care. Paradigm Health brings a research operation with the technology: patient identification, eSource and data capture embedded in the provider's workflow, its own recruitment coordinators and eligibility specialists, and, since December 2025, Flatiron Health's former clinical research business. Triomics gives the cancer center's own staff the tools. Its OncoLLM models, tuned further on each institution's records, read the whole chart; Prism screens every scheduled patient against every open trial each day and delivers a worklist with a citation behind each answer. It runs inside Epic, OncoEMR and iKnowMed, and its matching method is published in npj Digital Medicine. Choose Paradigm when the health system wants a partner to run research with it; choose Triomics when the research team wants to keep the work and screen faster.
- Research operations, coordinators and eSource provided with the platform.
- Matching that shows reviewers the clinical notes behind each candidate.
- A Research Collaboration Agreement with the FDA and a network including sites in Japan and Israel.
- Daily screening of every scheduled patient against every open trial, with cited answers.
- Oncology models tuned on each institution's own records, running inside the EHR.
- Pre charting and registry abstraction from the same chart reading.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Paradigm Health and Triomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Paradigm Health | Triomics |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2021 | 2021 |
| Headquarters | Columbus, Ohio, United States | New York, New York, United States |
| Website | paradigmhealth.ai | triomics.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Paradigm Health
-
Clinical evidence
Paradigm Health reported a retrospective evaluation of its trial screening platform on records from 3,027 lung cancer patients at Japan's National Cancer Center Hospital East, presented at ESMO 2026 with Fujitsu.
Source -
Clinical evidence
Ochsner Health reported outcomes from deploying Paradigm Health's LLM-based clinical trial recruitment platform across its 47 hospitals and 370 health centers.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Clinical trial platform that embeds patient identification, eSource and data capture inside provider organizations so trials can run in routine care, paired with its own recruitment coordinators and eligibility specialists. Matching combines structured-data prefilters with large language models that reason over full clinical notes, showing reviewers the documents behind each candidate.
Source: AI Health Index, September 2026
Oncology AI that reads the whole patient chart. OncoLLM, a family of oncology-tuned models tuned further on each institution's records, reads every note, report, scan and fax and returns structured answers with a citation to the line in the chart behind each one.
Source: AI Health Index, September 2026
Questions buyers ask
How do Paradigm Health and Triomics handle patient data?
For Paradigm Health, the platform reads provider records inside participating organizations, passes candidates and study data to sponsors, and in FDA's Real-Time Clinical Trials pilot sends pre-defined safety, efficacy and data quality signals to the Agency during a study. Source-linked case report forms let monitors check a value against the originating record.
With Triomics, the company says its models are tuned on each institution's own records with human feedback and deployed as a customized model per partner, and Symphony learns each physician's note style; the privacy page points to a General Privacy Policy on HIPAA. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Paradigm Health and Triomics?
Ghanim and colleagues (npj Health Systems, 2026; Flatiron Health with Johnson and Johnson, before Paradigm bought the business) ran a prospective study at four community oncology sites: 82 patients in 11 months, 0.59 percent missing data, 91 percent of 4,568 data points eligible for automated EHR-to-EDC transfer, and fewer than 2 percent queried.
For Triomics, the PRISM trial-matching system was published in npj Digital Medicine (October 2024), reporting 95 percent accuracy in matching patients to trials against expert review. An ASCO 2025 abstract co-authored with a leading academic medical center reports enterprise screening with OncoLLM producing 40 percent more trial matches and a 30 percent lift in trial accruals. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How much do Paradigm Health and Triomics leave to the clinician?
With Paradigm Health, the AI continuously monitors eligibility and prioritizes candidates with rationale and supporting clinical context; the company's eligibility specialists and site teams review, confirm eligibility and follow up, re-screening as records change; final eligibility and consent rest with the research team. Nothing the models do reaches a patient without that review.
In Triomics' case, each value carries a citation that opens the source line in the chart, and audit trails are native. The company describes this as 'cited, auditable, never a black box', a claim about the basis of each output that the citations back up. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Neither company publishes a price.
Ask both how many screened patients go on to enroll, and how a wrong match is caught before a patient is approached.